What adjuvant therapy would you offer a TNBC patient with residual disease after receiving the neoadjuvant KEYNOTE-522 regimen?

1 Answers

Mednet Member

Medical Oncology · Cedars-Sinai Medical Center

Safety is pembro and cape was provided in phase I trials. Risk and benefit weighing is important when discussing with patients.